Heparin as an inhibitor of cancer progression - PubMed

Review

Heparin as an inhibitor of cancer progression

Lubor Borsig. Prog Mol Biol Transl Sci. 2010.

Free article

Abstract

Heparin is frequently used in the treatment of cancer-associated thromboembolism. Accumulating clinical evidence indicates that cancer patients treated with unfractionated and low-molecular weight heparin (LMWH) survive longer than patients treated by other anticoagulants, especially patients in the early stage of the disease. Experimental analysis from a number of animal models constantly provides evidence for the ability of heparin to attenuate metastasis. The non-anticoagulant activity of heparin on metastasis includes the ability to inhibit cell-cell-interaction through blocking of P- and L-selectin, to inhibit extracellular matrix protease heparanase, and to inhibit angiogenesis. This chapter summarizes current experimental evidence on the biology of heparin during cancer progression, with the focus on potential mechanism of heparin antimetastatic activity.

Similar articles

• Antimetastatic activities of heparins and modified heparins. Experimental evidence.

  Borsig L. Borsig L. Thromb Res. 2010 Apr;125 Suppl 2:S66-71. doi: 10.1016/S0049-3848(10)70017-7. Thromb Res. 2010. PMID: 20434009 Review.

• Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis.

  Borsig L. Borsig L. Semin Thromb Hemost. 2007 Jul;33(5):540-6. doi: 10.1055/s-2007-982086. Semin Thromb Hemost. 2007. PMID: 17629852 Review.

• [Do anticoagulants improve survival in patients with cancer?].

  Meyer G. Meyer G. Pathol Biol (Paris). 2008 Jun;56(4):233-8. doi: 10.1016/j.patbio.2008.03.001. Epub 2008 May 5. Pathol Biol (Paris). 2008. PMID: 18456421 French.

• Antitumor and antimetastatic effect of warfarin and heparins.

  Bobek V, Kovarík J. Bobek V, et al. Biomed Pharmacother. 2004 May;58(4):213-9. doi: 10.1016/j.biopha.2003.11.007. Biomed Pharmacother. 2004. PMID: 15183845 Review.

• Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.

  Mousa SA, Petersen LJ. Mousa SA, et al. Thromb Haemost. 2009 Aug;102(2):258-67. doi: 10.1160/TH08-12-0832. Thromb Haemost. 2009. PMID: 19652876 Review.

Cited by

• Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin.

  Baik JY, Dahodwala H, Oduah E, Talman L, Gemmill TR, Gasimli L, Datta P, Yang B, Li G, Zhang F, Li L, Linhardt RJ, Campbell AM, Gorfien SF, Sharfstein ST. Baik JY, et al. Biotechnol J. 2015 Jul;10(7):1067-81. doi: 10.1002/biot.201400665. Epub 2015 Jun 24. Biotechnol J. 2015. PMID: 26037948 Free PMC article.

• Steering Mast Cells or Their Mediators as a Prospective Novel Therapeutic Approach for the Treatment of Hematological Malignancies.

  Mehtani D, Puri N. Mehtani D, et al. Front Oncol. 2021 Sep 24;11:731323. doi: 10.3389/fonc.2021.731323. eCollection 2021. Front Oncol. 2021. PMID: 34631562 Free PMC article. Review.

• Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas.

  Bokas A, Papakotoulas P, Sarantis P, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Bokas A, et al. Cancers (Basel). 2020 Feb 13;12(2):432. doi: 10.3390/cancers12020432. Cancers (Basel). 2020. PMID: 32069809 Free PMC article. Review.

• In Surgical Colon Cancer Patients Extended-Duration Thromboprophylaxis (30 days) with the Highest Dose of Tinzaparin (4,500 IU s.c./q.d.) Normalizes the Postoperative VEGF Levels.

  Mitsis M, Koliou P, Bali C, Ntounousi E, Tatsis V, Nousias V, Lianos GD, Vartholomatos G, Nastos D. Mitsis M, et al. J Cancer. 2017 Aug 25;8(15):2899-2906. doi: 10.7150/jca.20107. eCollection 2017. J Cancer. 2017. PMID: 28928880 Free PMC article.

• The role of extracellular vesicle fusion with target cells in triggering systemic inflammation.

  Papareddy P, Tapken I, Kroh K, Varma Bhongir RK, Rahman M, Baumgarten M, Cim EI, Györffy L, Smeds E, Neumann A, Veerla S, Olinder J, Thorlacus H, Ryden C, Bartakova E, Holub M, Herwald H. Papareddy P, et al. Nat Commun. 2024 Feb 7;15(1):1150. doi: 10.1038/s41467-024-45125-1. Nat Commun. 2024. PMID: 38326335 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Zurich Open Access Repository and Archive

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information